RT Journal Article SR Electronic T1 Humoral and cellular responses to SARS-CoV-2 vaccination in patients with lymphoid malignancies JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.12.08.21266760 DO 10.1101/2021.12.08.21266760 A1 Lim, Sean H. A1 Campbell, Nicola A1 Stuart, Beth A1 Johnson, Marina A1 Joseph-Pietras, Debora A1 Kelly, Adam A1 Jeffrey, Danielle A1 Turaj, Anna H. A1 Rolfvondenbaumen, Kate A1 Galloway, Celine A1 Wynn, Thomas A1 Coleman, Adam R. A1 Ward, Benjamin A1 Long, Karen A1 Bates, Andrew T. A1 Ayres, Diana A1 Lown, Robert A1 Falconer, Janlyn A1 Brake, Oliver A1 Batchelor, James A1 Willimott, Victoria A1 Al-Naeeb, Anna Bowzyk A1 Robinson, Lisa A1 O’Callaghan, Ann A1 Collins, Graham P. A1 Menne, Tobias A1 Faust, Saul N. A1 Fox, Christopher P. A1 Ahearne, Matthew A1 Johnson, Peter W.M. A1 Davies, Andrew J. A1 Goldblatt, David YR 2021 UL http://medrxiv.org/content/early/2021/12/08/2021.12.08.21266760.abstract AB SARS-CoV-2 vaccination protects against COVID-19. Antibodies and antigen-specific T-cell responses against the spike domain can be used to measure vaccine immune response. Individuals with lymphoma have defects in humoral and cellular immunity that may compromise vaccine response. In this prospective observational study of 457 participants with lymphoma, 52% of participants vaccinated on treatment had undetectable anti-spike IgG antibodies compared to 9% who were not on treatment. Marked impairment was observed in those receiving anti- CD20 antibody within 12 months where 60% had undetectable antibodies compared to 11% on chemotherapy, which persisted despite three vaccine doses. Overall, 63% had positive T-cell responses irrespective of treatment. Individuals with indolent B-cell lymphoma have impaired antibody and cellular responses that were independent of treatment. The significant reduction and heterogeneity in immune responses in these individuals emphasise the urgent need for immune response monitoring and alternative prophylactic strategies to protect against COVID- 19.Competing Interest StatementSHL, NC, MJ, DJP, AO, AK, ARC, AHT, KL, DJ, BW, TW, ATB, KR, BS, CG, DA, JF, OB, JB, VM, ABAN, LR, TM, SF, PWMJ and DG declare no competing interests. CF receives consultancy fees from AstraZeneca and participates in an advisory board for AstraZeneca, MA receives research funding from Pfizer, GPC receives research funding from Pfizer and participates in advisory boards for AstraZeneca and Pfizer, RL reports receiving speaker fees and honoraria from Janssen and AJD reports receiving research funding and honoraria from AstraZeneca and Janssen.Funding StatementThe PROSECO study is funded by the Blood Cancer UK Vaccine Research Collaborative, which is led by Blood Cancer UK in partnership with Myeloma UK, Anthony Nolan and the British Society for Haematology (21009), and supported by Cancer Research UK Advanced Clinician Scientist Fellowship to SHL (A27179), the Cancer Research UK/NIHR Southampton Experimental Cancer Medicine Centre (A25141), the NIHR Southampton Clinical Research Facility (Southampton Research Biorepository) and NIHR Southampton Biomedical Research Centre. DG receives support from the NIHR Great Ormond Street Biomedical Research Centre.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the UK National Health Service Health Research Authority (North West-Liverpool Central Research Ethics Committee, IRAS 294739; 233768).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the corresponding author.